Volume : 11, Issue : 11, November – 2024
Title:
RANIBIZUMAB: A NOVEL THERAPEUTIC AGENT
Authors :
Mr. Sane Kumar Reddy * D. C. Bhuvaneswar Rao, Dr. K. Venugopal
Abstract :
Your study on the efficacy of laser combination therapy versus Ranibizumab monotherapy for anti-VEGF-resistant diabetic macular edema (DME) presents some important findings. Here’s a concise summary of the key points:
To evaluate the effectiveness of laser combination therapy alongside anti-VEGF compared to Ranibizumab monotherapy in patients resistant to anti-VEGF treatment for DME.Best- Corrected Visual Acuity (BCVA): There was no significant improvement in BCVA between the two groups (laser combination therapy: +3.2 letters; Ranibizumab monotherapy: -7.5 letters; p
= 0.165).BCVA Over Time: No significant change from visit 1 to visit 7 in either group (laser combination: 64.3 to 70.3 letters, p = 0.537; Ranibizumab monotherapy: 72.3 to 64.8 letters, p
= 0.554).Central Foveal Retinal Thickness: Both groups showed no significant changes (laser combination: +9.3%; Ranibizumab monotherapy: -7.3%; p = 0.926)Intravitreal Therapy Sessions: No significant difference in the number of Ranibizumab injections (laser combination: 5.2; monotherapy: 6.0; p = 0.237). Laser combination therapy did not demonstrate superior effectiveness over Ranibizumab monotherapy for patients with anti- VEGF-resistant DME. The study suggests considering alternative treatments for these patients.
Key Words: Age-related macular degeneration, choroidal neovascular membrane, Lucentis tm [ranibizumab injection], vascular endothelial growth factor
Cite This Article:
Please cite this article in press Sane Kumar Reddy et al., Ranibizumab: A Novel Therapeutic Agent..,Indo Am. J. P. Sci, 2024; 11 (11).
Number of Downloads : 10
References:
1. Wong WL et al., Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis.
2. Rosenfeld PJ et al., Brown DM et al., Heier JS et al., MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration.
3. Brown DM et al., Michels M et al., Kaiser PK et al., Heier JS et al., Sy JP et al., Ianchulev T; ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study.
4. Heier JS et al., Brown DM et al., Chong V, et al; VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.
5. Martin DF et al., Maguire MG et al., Fine SL et al; Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.
6. Rofagha S et al., Bhisitkul RB et al., Boyer DS et al., Saada SR et al., Zhang K et al.; SEVEN-UP Study Group. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP).
7. Varano M et al., Eter N et al., Win yard S et al., Wittrup-Jensen KU et al., Navarro R et al., Heraghty J et al. Current barriers to treatment for wet age-related macular degeneration (wAMD): findings from the wAMD patient and caregiver survey.
8. Agarwal A et al. et al., Rhoades WR et al., Hanout M, et al. Management of neovascular age-related macular degeneration: current state-of-the-art care for optimizing visual outcomes and therapies in development.
9. Spaide R et al. Ranibizumab according to need: a treatment for age-related macular degeneration.
10. Stewart MW et al. Individualized treatment of neovascular age-related macular degeneration: what are patients gaining? or losing?
11. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular Edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Early Treatment Diabetic Retinopathy Study Research Group.
12. Furashova et al., O., Strassburger et al., P., Becker et al., K. A. & Engelmann et al., K. Efficacy of combining intravitreal injections of ranibizumab with micro pulse diode laser versus intravitreal injections of ranibizumab alone in diabetic macular Edema (Recall): A single centre, randomised, controlled, non-inferiority clinical trial.
13. Murata, T. et al. The randomized ZIPANGU trial of ranibizumab and adjunct laser for macular Edema following branch retinal vein occlusion in treatment-naïve patients. Sci. Rep. 11, 551.
14. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular Edema. Ophthalmology 115, 1447–1449, 1449.e1441– 1410
15. Martidis, A. et al. Intravitreal triamcinolone for refractory diabetic macular Edema. Ophthalmology 109, 920–927.
16. Rosenblatt et al., B. J., Shah et al., G. K., Sharma et al., S. & Bakal et al., J. Pars plana vitrectomy with internal limiting membrane Tomy for refractory diabetic macular edema without a taut posterior hyaloid. Graef ’s Arch. Clin.
17. Tachi et al., N. & Ogino et al., N. Vitrectomy et al. for diffuse macular Edema in cases of diabetic retinopathy.
18. Inagaki et al., K., Hamada et al., M. & Oshkosh et al., K. Minimally invasive laser treatment combined with intravitreal injection of anti-vascular endothelial growth factor for diabetic macular oedema.
19. Kanar et al., H. S., Arsan et al, A., Altun et al., A., Akı et al., S. F. & Hacısalihoglu et al., A. Can subthreshold micro pulse yellow laser treatment change the anti-vascular endothelial growth factor algorithm in diabetic macular Edema? A randomized clinical trial. Indian J.
20. Nozaki, M., Ando, R., Kimura, T., Kato, F. & Yasukawa, T. The role of laser photocoagulation in treating diabetic macular Edema in the era of intravitreal drug administration: A descriptive review.
21. Silva R, Axer-Siegel R, Eldem B, Guymer R, Kirchhof B, Papp A, et al. The SECURE study: long-term safety of ranibizumab 0.5 mg in neovascular age-related macular degeneration. Ophthalmology. 2013;120(1):130–9.
22. Penedones A, Mendes D, Alves C, Batel MF. Safety monitoring of ophthalmic biologics: a systematic review of pre- and post-marketing safety data. J Ocul Pharmacal Ther. 2014;30(9):729–
23. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897–908.
24. Antoszyk AN, Tuomi L, Chung CY, Singh A. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmic. 2008;145(5):862–74.
25. Leveziel N, Pelat T, Watier H, Thullier P, Souied EH. Detection of ant ranibizumab antibodies among patients with exudative age-related macular degeneration. Ophthalmological. 2014;232(1):53–6.
26. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmic. 2008;145(2):239–48.